GSK reaches settlement over Zantac lawsuit

Receive free GSK PLC updates

We’ll send you a myFT Daily Digest email rounding up the latest GSK PLC news every morning.

Pharmaceutical group GSK has reached a settlement in a lawsuit over allegations its heartburn medication Zantac caused cancer, avoiding a landmark trial that was due to start in California next month.

The UK company said on Friday it had reached a settlement with James Goetz, who filed a suit in a California state court.

The settlement reflected its desire “to avoid distraction related to protracted litigation in this case”, GSK said, without providing details of the agreement.

“GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases,” it added.